Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 11/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | IL1B | P01584 | 5/20 | 0.34 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.34 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.34 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | SPR | P35270 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31199631 | 1.00 | NLRP3 (0.48) | NLRP3USP30HCRTR1HCRTR2IL1B | |
| SCHEMBL31199534 | 0.92 | NLRP3 (0.49) | NLRP3USP30HCRTR1HCRTR2IL1B | |
| SCHEMBL31199275 | 0.90 | NLRP3 (0.40) | NLRP3USP30HCRTR1HCRTR2IL1B | |
| SCHEMBL31199341 | 0.89 | NLRP3 (0.46) | NLRP3IL1B | |
| SCHEMBL31199271 | 0.89 | NLRP3 (0.46) | NLRP3IL1B | |
| SCHEMBL31199458 | 0.89 | NLRP3 (0.46) | NLRP3IL1B | |
| SCHEMBL31199524 | 0.89 | NLRP3 (0.46) | NLRP3IL1B | |
| SCHEMBL31199256 | 0.88 | NLRP3 (0.44) | NLRP3USP30HCRTR1HCRTR2SMARCA2 | |
| SCHEMBL31199709 | 0.88 | NLRP3 (0.61) | NLRP3USP30IL1B | |
| SCHEMBL31199492 | 0.88 | NLRP3 (0.61) | NLRP3USP30IL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680601-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | Sanofi (FR) | 2026-01-21 | — | — | EP | claimed |
| US-20240360151-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | SANOFI (FR) | 2024-10-31 | — | — | US | claimed |
| WO-2024188994-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | SANOFI (FR) | 2024-09-19 | — | — | WO | claimed |
| EP-4680601-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | Sanofi (FR) | 2026-01-21 | — | — | EP | disclosed |
| US-20240360151-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | SANOFI (FR) | 2024-10-31 | — | — | US | disclosed |
| WO-2024188994-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | SANOFI (FR) | 2024-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360151-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | NLRP3, NOD1, NLRP1 | NLRP3 1/4885USP30 3707/4885HCRTR1 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.